Respiratory medicine

LONDON: GSK plc announced Monday that it has entered into agreements with China-based Hengrui Pharma to co-develop up to 12 innovative medicines spanning respiratory, immunology, inflammation and oncology indications, marking a major expansion of the British pharmaceutical giant’s pipeline beyond 2031. The collaboration includes an exclusive license for HRS-9821, a potential best-in-class PDE3/4 inhibitor in…